| Title: |
Predictors of mortality and therapeutic efficacy in carbapenem-resistant Acinetobacter baumannii bacteremia. |
| Authors: |
Russo, Alessandro1,2 (AUTHOR) a.russo@unicz.it; Gullì, Sara Palma1 (AUTHOR); Vena, Antonio3 (AUTHOR); Spadafora, Luigi4,5 (AUTHOR); Bernardi, Marco4,5 (AUTHOR); Corcione, Silvia6 (AUTHOR); Ceccarelli, Giancarlo7 (AUTHOR); Alessandri, Francesco7 (AUTHOR); Mastroianni, Claudio Maria8 (AUTHOR); Oliva, Alessandra8 (AUTHOR); Venanzi Rullo, Emmanuele9 (AUTHOR); Caviglia, Giuseppe9 (AUTHOR); Cortegiani, Andrea10,11 (AUTHOR); Ippolito, Mariachiara10,11 (AUTHOR); Nunnari, Giuseppe12 (AUTHOR); Di Gennaro, Francesco13 (AUTHOR); Saracino, Annalisa13 (AUTHOR); Marino, Andrea14 (AUTHOR); Cacopardo, Bruno14 (AUTHOR); Tiseo, Giusy15,16 (AUTHOR) |
| Source: |
Journal of Infection. May2026, Vol. 92 Issue 5, pN.PAG-N.PAG. 1p. |
| Abstract: |
Bacteremia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) is associated with high morbidity and mortality. The primary objective was to identify clinical and therapeutic factors associated with 14- and 30-day mortality following infection onset. This was a prospective, observational, multicenter study conducted across 52 Italian centers. Over an 18-month period, adult hospitalized patients with CRAB bacteremia were enrolled. Among 398 patients with CRAB bacteremia, sources were mainly CVC-related or primary, with 14- and 30-day mortality rates of 22% and 27% respectively. Cox regression analysis identified male sex (p=0.006), and chronic kidney disease (p=0.016) as independent predictors of 14-day mortality, while colistin-containing regimen (p=0.014), and cefiderocol-containing-regimen (p |
| Database: |
Supplemental Index |